Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Drug Pricing Clinical Trials Drug Safety Weight Loss Weight Loss Drugs Drug Regulation Cancer Treatment Medications

Plaintiff Firms Intensify Biotech Securities Suits as Key Deadlines Near for Nektar, uniQure and REGENXBIO

Upcoming lead-plaintiff decisions will shape who directs these early-stage cases.

Pfizer, Valneva Lyme Vaccine Tops 70% in Phase 3 but Misses Primary Endpoint

Macau Authorizes ImmunityBio’s Anktiva Plus BCG for BCG‑Unresponsive Bladder Cancer

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Karyopharm Raises $30 Million in RA Capital Private Placement

Stories older than 24h

Apogee to Report 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis Today

India Rolls Out Low-Cost Semaglutide Generics After Patent Expiry

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety Disclosures

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

FDA Upgrades Children’s Ibuprofen Recall to Class II Over Reports of Foreign Material

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

FDA Approves Nivolumab Plus AVD as First-Line Therapy for Advanced Hodgkin Lymphoma

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

Taysha Advances Rett Gene Therapy Program With Pivotal Dosing, FDA Alignment and Q2 Data Timeline

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

Analyses Find Limited Savings as TrumpRx Reaches 54 Drugs

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy